Cargando…

The establishment of a bank of stored clinical bone marrow stromal cell products

BACKGROUND: Bone marrow stromal cells (BMSCs) are being used to treat a variety of conditions. For many applications a supply of cryopreserved products that can be used for acute therapy is needed. The establishment of a bank of BMSC products from healthy third party donors is described. METHODS: Th...

Descripción completa

Detalles Bibliográficos
Autores principales: Sabatino, Marianna, Ren, Jiaqiang, David-Ocampo, Virginia, England, Lee, McGann, Michael, Tran, Minh, Kuznetsov, Sergei A, Khuu, Hanh, Balakumaran, Arun, Klein, Harvey G, Robey, Pamela G, Stroncek, David F
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2012
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3309931/
https://www.ncbi.nlm.nih.gov/pubmed/22309358
http://dx.doi.org/10.1186/1479-5876-10-23
_version_ 1782227581753360384
author Sabatino, Marianna
Ren, Jiaqiang
David-Ocampo, Virginia
England, Lee
McGann, Michael
Tran, Minh
Kuznetsov, Sergei A
Khuu, Hanh
Balakumaran, Arun
Klein, Harvey G
Robey, Pamela G
Stroncek, David F
author_facet Sabatino, Marianna
Ren, Jiaqiang
David-Ocampo, Virginia
England, Lee
McGann, Michael
Tran, Minh
Kuznetsov, Sergei A
Khuu, Hanh
Balakumaran, Arun
Klein, Harvey G
Robey, Pamela G
Stroncek, David F
author_sort Sabatino, Marianna
collection PubMed
description BACKGROUND: Bone marrow stromal cells (BMSCs) are being used to treat a variety of conditions. For many applications a supply of cryopreserved products that can be used for acute therapy is needed. The establishment of a bank of BMSC products from healthy third party donors is described. METHODS: The recruitment of healthy subjects willing to donate marrow for BMSC production and the Good Manufacturing Practices (GMP) used for assessing potential donors, collecting marrow, culturing BMSCs and BMSC cryopreservation are described. RESULTS: Seventeen subjects were enrolled in our marrow collection protocol for BMSC production. Six of the 17 subjects were found to be ineligible during the donor screening process and one became ill and their donation was cancelled. Approximately 12 ml of marrow was aspirated from one posterior iliac crest of 10 donors; one donor donated twice. The BMSCs were initially cultured in T-75 flasks and then expanded for three passages in multilayer cell factories. The final BMSC product was packaged into units of 100 × 10(6 )viable cells, cryopreserved and stored in a vapor phase liquid nitrogen tank under continuous monitoring. BMSC products meeting all lot release criteria were obtained from 8 of the 11 marrow collections. The rate of growth of the primary cultures was similar for all products except those generated from the two oldest donors. One lot did not meet the criteria for final release; its CD34 antigen expression was greater than the cut off set at 5%. The mean number of BMSC units obtained from each donor was 17 and ranged from 3 to 40. CONCLUSIONS: The production of large numbers of BMSCs from bone marrow aspirates of healthy donors is feasible, but is limited by the high number of donors that did not meet eligibility criteria and products that did not meet lot release criteria.
format Online
Article
Text
id pubmed-3309931
institution National Center for Biotechnology Information
language English
publishDate 2012
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-33099312012-03-23 The establishment of a bank of stored clinical bone marrow stromal cell products Sabatino, Marianna Ren, Jiaqiang David-Ocampo, Virginia England, Lee McGann, Michael Tran, Minh Kuznetsov, Sergei A Khuu, Hanh Balakumaran, Arun Klein, Harvey G Robey, Pamela G Stroncek, David F J Transl Med Methodology BACKGROUND: Bone marrow stromal cells (BMSCs) are being used to treat a variety of conditions. For many applications a supply of cryopreserved products that can be used for acute therapy is needed. The establishment of a bank of BMSC products from healthy third party donors is described. METHODS: The recruitment of healthy subjects willing to donate marrow for BMSC production and the Good Manufacturing Practices (GMP) used for assessing potential donors, collecting marrow, culturing BMSCs and BMSC cryopreservation are described. RESULTS: Seventeen subjects were enrolled in our marrow collection protocol for BMSC production. Six of the 17 subjects were found to be ineligible during the donor screening process and one became ill and their donation was cancelled. Approximately 12 ml of marrow was aspirated from one posterior iliac crest of 10 donors; one donor donated twice. The BMSCs were initially cultured in T-75 flasks and then expanded for three passages in multilayer cell factories. The final BMSC product was packaged into units of 100 × 10(6 )viable cells, cryopreserved and stored in a vapor phase liquid nitrogen tank under continuous monitoring. BMSC products meeting all lot release criteria were obtained from 8 of the 11 marrow collections. The rate of growth of the primary cultures was similar for all products except those generated from the two oldest donors. One lot did not meet the criteria for final release; its CD34 antigen expression was greater than the cut off set at 5%. The mean number of BMSC units obtained from each donor was 17 and ranged from 3 to 40. CONCLUSIONS: The production of large numbers of BMSCs from bone marrow aspirates of healthy donors is feasible, but is limited by the high number of donors that did not meet eligibility criteria and products that did not meet lot release criteria. BioMed Central 2012-02-06 /pmc/articles/PMC3309931/ /pubmed/22309358 http://dx.doi.org/10.1186/1479-5876-10-23 Text en Copyright ©2012 Sabatino et al; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Methodology
Sabatino, Marianna
Ren, Jiaqiang
David-Ocampo, Virginia
England, Lee
McGann, Michael
Tran, Minh
Kuznetsov, Sergei A
Khuu, Hanh
Balakumaran, Arun
Klein, Harvey G
Robey, Pamela G
Stroncek, David F
The establishment of a bank of stored clinical bone marrow stromal cell products
title The establishment of a bank of stored clinical bone marrow stromal cell products
title_full The establishment of a bank of stored clinical bone marrow stromal cell products
title_fullStr The establishment of a bank of stored clinical bone marrow stromal cell products
title_full_unstemmed The establishment of a bank of stored clinical bone marrow stromal cell products
title_short The establishment of a bank of stored clinical bone marrow stromal cell products
title_sort establishment of a bank of stored clinical bone marrow stromal cell products
topic Methodology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3309931/
https://www.ncbi.nlm.nih.gov/pubmed/22309358
http://dx.doi.org/10.1186/1479-5876-10-23
work_keys_str_mv AT sabatinomarianna theestablishmentofabankofstoredclinicalbonemarrowstromalcellproducts
AT renjiaqiang theestablishmentofabankofstoredclinicalbonemarrowstromalcellproducts
AT davidocampovirginia theestablishmentofabankofstoredclinicalbonemarrowstromalcellproducts
AT englandlee theestablishmentofabankofstoredclinicalbonemarrowstromalcellproducts
AT mcgannmichael theestablishmentofabankofstoredclinicalbonemarrowstromalcellproducts
AT tranminh theestablishmentofabankofstoredclinicalbonemarrowstromalcellproducts
AT kuznetsovsergeia theestablishmentofabankofstoredclinicalbonemarrowstromalcellproducts
AT khuuhanh theestablishmentofabankofstoredclinicalbonemarrowstromalcellproducts
AT balakumaranarun theestablishmentofabankofstoredclinicalbonemarrowstromalcellproducts
AT kleinharveyg theestablishmentofabankofstoredclinicalbonemarrowstromalcellproducts
AT robeypamelag theestablishmentofabankofstoredclinicalbonemarrowstromalcellproducts
AT stroncekdavidf theestablishmentofabankofstoredclinicalbonemarrowstromalcellproducts
AT sabatinomarianna establishmentofabankofstoredclinicalbonemarrowstromalcellproducts
AT renjiaqiang establishmentofabankofstoredclinicalbonemarrowstromalcellproducts
AT davidocampovirginia establishmentofabankofstoredclinicalbonemarrowstromalcellproducts
AT englandlee establishmentofabankofstoredclinicalbonemarrowstromalcellproducts
AT mcgannmichael establishmentofabankofstoredclinicalbonemarrowstromalcellproducts
AT tranminh establishmentofabankofstoredclinicalbonemarrowstromalcellproducts
AT kuznetsovsergeia establishmentofabankofstoredclinicalbonemarrowstromalcellproducts
AT khuuhanh establishmentofabankofstoredclinicalbonemarrowstromalcellproducts
AT balakumaranarun establishmentofabankofstoredclinicalbonemarrowstromalcellproducts
AT kleinharveyg establishmentofabankofstoredclinicalbonemarrowstromalcellproducts
AT robeypamelag establishmentofabankofstoredclinicalbonemarrowstromalcellproducts
AT stroncekdavidf establishmentofabankofstoredclinicalbonemarrowstromalcellproducts